Extended-release Guanfacine Hydrochloride for ADHD
This study is completed in the United States, in France, in Canada, .... It is testing Extended-release Guanfacine Hydrochloride for ADHD.
ADHDDrugFrom 6 Years to 17 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Extended-release Guanfacine Hydrochloride may be useful for adolescents experiencing ADHD.
What would participation involve?
Participants may receive Extended-release Guanfacine Hydrochloride, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Belgium, in Canada, and in France.
Who is it mainly for?
This study appears to be mainly for adolescents with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: May 11, 2010
Recruitment status
Completed
Enrollment listed in the registry
528
Sponsor
Shire
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Canada, ...
Age range
From 6 Years to 17 Years
Official registry ID
NCT01081145
Official title
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01081145. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
Azienda Osp. Fatebenefratelli - Polo Territoriale UONPIA
Milan
Site status: Not listed — confirm with the team
Azienda ULSS 16 Padova
Padova
Site status: Not listed — confirm with the team
Drottning Silvias Barnsjukhus
Roma
Site status: Not listed — confirm with the team
Università Cattolica del Sacro Cuore
Roma
Site status: Not listed — confirm with the team
Netherlands · 3 sites
FlevoResearch
Almere Stad, Flevoland
Site status: Not listed — confirm with the team
Academisch Ziekenhuis Maastricht
Maastricht, Limburg
Site status: Not listed — confirm with the team
Mondriaan Zorggroep Heerlen, Kinder en Jeugdp sychiatrie
Maastricht
Site status: Not listed — confirm with the team
Spain · 7 sites
Hospital Son Llàtzer, Laboratorio de Neurociencias IUNICS
Palma, Balearic Islands
Site status: Not listed — confirm with the team
Policlínica Guipuzkoa
Donostia / San Sebastian, Guipuzcoa
Site status: Not listed — confirm with the team
Hospital Fundacion Alcorcon
Alcorcón, Madrid
Site status: Not listed — confirm with the team
Clínica Universitaria de Navarra
Pamplona, Navarre
Site status: Not listed — confirm with the team
Hospital Universitari Vall d'Hebron
Barcelona
Site status: Not listed — confirm with the team
Hospital Infanta Leonor
Madrid
Site status: Not listed — confirm with the team
Instituto Valenciano de Neurología Pediatrica
Valencia
Site status: Not listed — confirm with the team
Sweden · 1 site
Barn och Ungdomsmedicin klinik Mölnlycke
Mölnlycke
Site status: Not listed — confirm with the team
United Kingdom · 7 sites
Norfolk Community Health and Care NHS Trust
Norwich, England
Site status: Not listed — confirm with the team
Ryegate Children's Centre
Sheffield, England
Site status: Not listed — confirm with the team
Centenary House Child and Adolescent Mental Health Services
Sheffield, England
Site status: Not listed — confirm with the team
Queen Elizabeth II Hospital
Welwyn Garden City, England
Site status: Not listed — confirm with the team
Thurrock Community Hospital
Grays
Site status: Not listed — confirm with the team
Royal Liverpool University Hospital
Liverpool
Site status: Not listed — confirm with the team
Lister Hospital
Stevenage
Site status: Not listed — confirm with the team
United States · 27 sites
Harmonex Neuroscience Research
Dothan, Alabama
Site status: Not listed — confirm with the team
Clinical Study Centers, LLC
Little Rock, Arkansas
Site status: Not listed — confirm with the team
Psychiatric Centers at San Diego, Feighner Research
San Diego, California
Site status: Not listed — confirm with the team
Encompass Clinical Research - North Coast
Spring Valley, California
Site status: Not listed — confirm with the team
Elite Clinical Trials, Inc.
Wildomar, California
Site status: Not listed — confirm with the team
Florida Clinical Research Center, LLC
Bradenton, Florida
Site status: Not listed — confirm with the team
Sarkis Clinical Trials
Gainesville, Florida
Site status: Not listed — confirm with the team
Amedica Research Institute, Inc.
Hialeah, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Site status: Not listed — confirm with the team
Florida Clinical Research Center, LLC
Maitland, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Site status: Not listed — confirm with the team
AMR-Baber Research Inc.
Naperville, Illinois
Site status: Not listed — confirm with the team
Goldpoint Clinical Research, LLC
Indianapolis, Indiana
Site status: Not listed — confirm with the team
Louisiana Research Associates, Inc.
New Orleans, Louisiana
Site status: Not listed — confirm with the team
Delmarva Family Resources
Salisbury, Maryland
Site status: Not listed — confirm with the team
University of Nebraska Medical Center
Omaha, Nebraska
Site status: Not listed — confirm with the team
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Mount Sinai School of Medicine
New York, New York
Site status: Not listed — confirm with the team
Triangle Neuropsychiatry, PLLC
Durham, North Carolina
Site status: Not listed — confirm with the team
Ohio State University, Nisonger Center
Columbus, Ohio
Site status: Not listed — confirm with the team
IPS Research Company
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
Salem, Oregon
Site status: Not listed — confirm with the team
CRI Worldwide, LLC
Philadelphia, Pennsylvania
Site status: Not listed — confirm with the team
FutureSearch Clinical Trials
Austin, Texas
Site status: Not listed — confirm with the team
ADHD Clinic of San Antonio
San Antonio, Texas
Site status: Not listed — confirm with the team
Alliance Research Group, LLC
Richmond, Virginia
Site status: Not listed — confirm with the team
Eastside Therapeutic Resource
Kirkland, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Extended-release Guanfacine Hydrochloride, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 17 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Shire, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
